Nucleic Acids Core Facility (David Lee, Ph.D., Faculty Director; Qing Yang, Ph.D., Facility Supervisor) The goal of the Nucleic Acids Core Facility (NACF) is to provide LCCC investigators with rapid access to high-quality oligonucleotides at the lowest practical cost. The facility provides investigators. with oligonucleotides for use in various applications, including DNA sequencing, PCR, cDNA synthesis, Northern/Southern Blots, in vitro mutagenesis, anti-sense inhibition of gene expression, and studies of DNA-protein interaction. The NACF also offers a wide range of custom synthesis options, including RNA oligomers, phosphorothioate oligomers, degenerate oligos, and oligo labeling with biotin, fluorescein, and many other compound. Over the past five years, the facility has implemented a number of measures that have improved services and reduced prices, including quality control measures, an on-line ordering system, purification of oligos, more efficient synthesis chemistries, a drying system, and a freezer program. These changes have resulted in several reductions in the price per base of 40 nmole scale synthesis, from $1.60 to its current level of $0.90, with plans for a further reduction to $0.80 per base in 1999 with the arrival of a new ABI 3948 DNA synthesizer. A continued high level of use by 87 peer-reviewed Cancer Center members accounted for over 83% of the facility's use in 1997-1998. CCSG support of $84,732 is requested, 89% of which will be used to support the facility's service-oriented personnel. This amount represents 26% of the facility's total budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-25
Application #
6398591
Study Section
Project Start
2000-05-01
Project End
2000-11-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447

Showing the most recent 10 out of 1525 publications